Yields and chondrogenic potential of primary synovial mesenchymal stem cells are comparable between rheumatoid arthritis and osteoarthritis patients

Stem Cell Research & Therapy
Yuji KohnoIchiro Sekiya

Abstract

Mesenchymal stem cells derived from the synovial membrane (synovial MSCs) are a candidate cell source for regenerative medicine of cartilage and menisci due to their high chondrogenic ability. Regenerative medicine can be expected for RA patients with the inflammation well-controlled as well as OA patients and transplantation of synovial MSCs would also be a possible therapeutic treatment. Some properties of synovial MSCs vary dependent on the diseases patients have, and whether or not the pathological condition of RA affects the chondrogenesis of synovial MSCs remains controversial. The purpose of this study was to compare the properties of primary synovial MSCs between RA and OA patients. Human synovial tissue was harvested during total knee arthroplasty from the knee joints of eight patients with RA and OA respectively. Synovial nucleated cells were cultured for 14 days. Total cell yields, surface markers, and differentiation potentials were analyzed for primary synovial MSCs. Nucleated cell number per 1 mg synovium was 8.4 ± 3.9 thousand in RA and 8.0 ± 0.9 thousand in OA. Total cell number after 14-day culture/1 mg synovium was 0.7 ± 0.4 million in RA and 0.5 ± 0.3 million in OA, showing no significant difference between i...Continue Reading

References

Mar 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ichiro SekiyaDarwin J Prockop
Feb 19, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Ichiro SekiyaDarwin J Prockop
Sep 14, 2006·Tissue Engineering·Shawn Patrick GroganPierre Mainil-Varlet
May 20, 2008·Analytical Biochemistry·Erik WillemsJo Vandesompele
Nov 11, 2009·Bulletin of Experimental Biology and Medicine·O A BuyanovskayaN P Bochkov
Mar 23, 2011·Journal of Cellular and Molecular Medicine·Hanae UeyamaKoji Kawakami
Dec 14, 2011·The New England Journal of Medicine·Iain B McInnes, Georg Schett
Jan 10, 2012·Cell Stem Cell·Luc SensebéUNKNOWN MSC Committee of the International Society for Cellular Therapy
Nov 22, 2013·PloS One·Masahiro KondoYoshiya Tanaka
Nov 19, 2014·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Yu MatsukuraIchiro Sekiya
Feb 17, 2015·Osteoarthritis and Cartilage·Y NakagawaI Sekiya
May 1, 2015·Clinical Orthopaedics and Related Research·Ichiro SekiyaHideyuki Koga

❮ Previous
Next ❯

Citations

May 8, 2020·Inflammation and Regeneration·Yoko Miura, Satoshi Kanazawa
Jan 13, 2018·Molecular Medicine Reports·Hao WangQingdong Shao
Sep 26, 2020·Nanomedicine·Shawn P GroganDarryl D D'Lima
Aug 30, 2020·Journal of Orthopaedic Science : Official Journal of the Japanese Orthopaedic Association·Hiroko UekiHideyuki Koga
Jul 10, 2021·Frontiers in Cell and Developmental Biology·Bo LiYi Men

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR
PCR
Protein Assay
biopsy
chromosomal aberrations

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.